A Study of Cell Therapy in COVID-19 Subjects With Acute Kidney Injury Who Are Receiving Renal Replacement Therapy

Inclusion Criteria: * Documented evidence of infection, e.g., positive PCR for COVID-19, positive blood cultures for systemic infection, active urinary sediment to suggest UTI, or any imaging supportive of a clinical diagnosis of infection, for example, pulmonary infiltrate on chest x-ray to suggest pneumonia, pancreatitis on CT imaging, abdominal collection, etc. * AKI as determined by the Investigator based on his/her clinical judgment * Receiving or planned to receive RRT in \< 24 hours * Able to tolerate indwelling intravascular access * Has tolerated CRRT for at least 6 hours prior to IP treatment * Have maintained hemodynamic stability for at least 6 hours prior to IP treatment with only minor changes in pressure support medication required (if used) * Vascular access (catheter placement) is patent and capable of supporting CRRT for the duration of IP treatment * Likely to require RRT for at least an additional 48 hours * Potassium level \>3.6 and \<5.5 mEq/L or \>3.6 and \< 5.5 mmol/L prior to IP treatment * SaO2 \> 92% prior to IP initiation * Blood pH \> 7.2 prior to IP initiation * Medically cleared to receive anticoagulation per institutional standard of care / PI prescribed protocol and meeting protocol defined anticoagulation targets prior to receipt of IP * Ability to give informed consent or have a legally authorized representative do so Exclusion Criteria: * Female subjects who are pregnant, planning to become pregnant, or lactating * MAP \<70 mmHg immediately prior to IP initiation * Systolic blood pressure \< 90 mmHg immediately prior to IP initiation * Mechanical ventilator support requiring FiO2 \> 80% prior to IP initiation * Receiving extracorporeal membrane oxygenation (ECMO) * Liver disease with Child Pugh score of \> 7 prior to IP initiation * High sensitivity cardiac Troponin level (hs-cTn) \> 100.0 ng/L prior to IP initiation or other equivalent Troponin test result prior to IP initiation * Hepatorenal syndrome * AKI due to post-renal outflow obstruction * Acute or chronic vasculitis of any etiology * Chronic systemic infection * Subjects with a past medical history of an inherited or acquired hypercoagulable condition independent of COVID-19 * Patients with a past medical history of an allergic response to MSC therapy * Participation in another interventional trial with the exception of studies of antivirals, corticosteroids, hydroxychloroquine, azithromycin, or angiotensin converting enzyme inhibitors/angiotensin receptor blockers (or related compounds) * Active malignancy(-ies) and/or receiving active treatment for a malignancy(-ies), with the exception of non-melanoma skin cancer * Subjects, who in the opinion of the Investigator, are likely to require escalating doses of vasopressors to attain and/or maintain hemodynamic stability, or subjects who have reached the institutionally defined maximum level of vasopressor support within 12 hours of intended IP integration * Imminent death in \<24 hours * Organ failure affecting more than 2 non-renal organs * Platelet count \<50,000/μL or other serious hematological abnormalities that would place subject in imminent danger of death * Lactate levels \>8 mmol/L suggestive of severe end-organ hypoperfusion prior to the time of IP integration * Any prior medical condition or recent surgical procedure, planned significant medical interventions or procedures that, in the judgment of the Investigator, would prevent the subject from safely participating in and/or completing all study requirements